Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Description and therapy of palmoplantar pustular psoriasis under IL-17A or dual IL-17A/F inhibition.

Journal of autoimmunity·2026
Same author

Combined immunosuppressive therapy in systemic sclerosis-associated interstitial lung disease: Phenotypes matter.

Autoimmunity reviews·2026
Same author

Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritis.

Frontiers in pharmacology·2026
Same author

Modulation of proinflammatory but not regulatory cytokines by in vitro JAK inhibition in peripheral blood B-cells of patients with psoriatic arthritis.

Journal of dermatological science·2026
Same author

Achievement and Maintenance of Remission with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in Italy: 1-Year Data from UPHOLD, a Prospective Real-World Observational Study.

Rheumatology and therapy·2026
Same author

Natural language processing to intercept rheumatoid and psoriatic arthritis from clinical notes in the Emergency Department.

Therapeutic advances in musculoskeletal disease·2026

相关实验视频

Updated: Jun 2, 2026

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

原发性胆道肝硬化的主要原因

Carlo Selmi1, Christopher L Bowlus, M Eric Gershwin

  • 1Department of Translational Medicine, IRCCS-Istituto Clinico Humanitas, University of Milan, Milan, Italy.

Lancet (London, England)
|May 3, 2011
PubMed
概括
此摘要是机器生成的。

原发性胆道硬化 (PBC) 是一种由抗线粒体抗体 (AMAs) 诊断的自身免疫性肝病. 用ursodeoxycholic酸治疗改善了预后,但对不响应者需要替代疗法.

相关实验视频

Last Updated: Jun 2, 2026

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

科学领域:

  • 肝病学 肝病学是一种肝病学.
  • 自体免疫学 自体免疫学
  • 胃肠病学 胃肠病学

背景情况:

  • 初级胆管缩 (PBC) 是一种慢性自身免疫性肝病,其特征是肝内胆道破坏.
  • 有证据表明,遗传倾向和环境因素 (化学物质,感染) 都会导致PBC的发病.
  • 增加的发病率可能与增强的诊断测试有关,而不是疾病发生率的真正增加.

研究的目的:

  • 总结目前对原发性胆汁硬化 (PBC) 病理生理学,诊断和管理的理解.
  • 突出抗线粒体抗体 (AMA) 在诊断中的作用.
  • 讨论ursodeoxycholic acid (UDCA) 治疗的影响以及替代疗法的需要.

主要方法:

  • 综述有关初级胆汁硬化现有的文献.
  • 对诊断标记物的分析,包括抗线粒体抗体 (AMAs).
  • 用ursodeoxycholic acid (UDCA) 治疗结果的评估.

主要成果:

  • 抗线粒体抗体 (AMA) 是大多数初级胆道硬化 (PBC) 病例的诊断标志,使得早期检测.
  • Ursodeoxycholic 酸 (UDCA) 是主要的治疗方法,可以减缓疾病的进展并改善预后.
  • 一部分患者对UDCA反应不足,需要探索替代治疗策略.

结论:

  • 原发性胆道硬化 (PBC) 是一种复杂的自身免疫性肝脏疾病,具有多因素的病因.
  • 早期诊断和UDCA治疗显著改善了患者的治疗结果.
  • 对于那些对当前疗法没有反应的患者来说,对替代治疗方法的进一步研究至关重要.